Studies have shown that active fund managers routinely underperform the S&P500 index*​

Dermata Therapeutics, Inc. (NASDAQ: DRMA)

DRMA Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
293.70%

DRMA Stock Analysis

DRMA PE Ratio:

DRMA PEG Ratio: Not Available

DRMA Forward EPS Growth (12 month): 0.00%

DRMA PS Ratio:

DRMA PSG Ratio:

DRMA Forward Revenue Growth (12 month): 400.00%

DRMA Articles

No data was found